Our Board

dawn-lee

Dawn Lee

Chief Scientific Officer

Dawn joined BresMed in 2010 and became a Board member in 2019. Before joining BresMed, Dawn worked for a transport economics consultancy, after gaining an MMath degree. She completed an MSc in health economics and decision modelling after starting at BresMed. She has experience in a number of disease areas and project types, and currently specializes in oncology modelling (in immuno-oncology in particular), early product assessment, health technology assessment (HTA) strategy, complex decision problems, models with complex statistical needs, end-to-end modelling solutions using R/R-SHINY and anything else “a bit weird and wonderful”. Dawn takes an advisory role on projects, with occasional hands-on technical modelling. Her role as Chief Scientific Officer focusses on achieving and maintaining BresMed’s position at the leading edge of health economics and outcomes research (HEOR), identifying trends within the industry and new types of work and methods for BresMed.

In her spare time, Dawn enjoys live music and science fiction and fantasy – particularly Dr Who.

What Dawn says about BresMed: “The team at BresMed let me take responsibility for the fun stuff – figuring out how we can use and operationalize new techniques in the market and solve the really complex problems.”

Curriculum vitae

Employment history

2019-Present   Chief Scientific Officer   BresMed

2018-2019   Frontiers Group   BresMed

2014-2018   Head of Health Economics Analysis team   BresMed

2010-2014   Health Economics roles   BresMed

2005-2010   Senior Consultant   AECOM

 

Research interests

Current research areas include:

  • Development of end to end modelling solutions using R / R-SHINY (increased efficiency of model development and ease of QC)
  • Methods for data combination across different sources (including observational data) to inform decision making
  • Methods for extrapolation of products where there is the potential for cure
  • Methods for handling competing risks and translation into later economic analyses e.g. multi state modelling (TSD 19)
  • Methods for handling non proportional hazards within relative treatment effect and translation into later extrapolation

 

Therapeutic areas of expertise

  • Acute thrombocytopenic purpura – strategic input and senior review of modelling for submission to NICE and SMC for this ultra-orphan product
  • Adrenal insufficiency – Developed a cost-utility Markov model to assess alternatives in treating adrenal insufficiency, for HTA submissions to the SMC and the AWMSG
  • Alzheimer’s/Schizophrenia – Oversaw reviews and critiques of existing cost-effectiveness analyses for schizophrenia and Alzheimer’s, to provide input into evidence collection and inform development of an early model to inform cost-effectiveness decisions
  • Alzheimer’s – Project lead for design and construction of a simulation model taking into account the interaction between cognition, function and behaviour. Specification of statistical analysis on observational data
  • Anorexia cachexia – Provided project leadership and strategic advice for the development of economic modelling, SLRs, and NICE and SMC submissions. Investigation of options for definition of response, utility mapping and stopping rules
  • Atrial fibrillation – lead development of a new economic model and updates to an existing economic model for follow-on indications for an existing AF product
  • Breast cancer – Provision of strategic advice for the development of a NICE submission and project lead for SMC submission for an I-O in mTNBC
  • Chronic lymphocytic leukaemia and indolent non-Hodgkin lymphoma – Provided project leadership and strategic advice for submissions to NICE, the SMC and the NCPE. Strategic approaches had to be devised for handling crossover and analysis of quality of life data for one submission and for simulating a comparator arm for a Phase II trial based on previous therapies received for the other
  • Crohn’s disease – Both development and provision of strategic advice for the development of early economic models including treatment sequencing. Analysis of data gaps and potential methods for data collection within and outside of planned trials
  • Congestive heart failure – Developed a simulation model in Simul8 based on patient level data with a user-friendly Excel interface capable of running PSA and DSA independently of Simul8 for all non-clinical parameters. Submitted successfully to the SMC and the AWMSG. Adapted the model for France, Greece, Canada and Spain. Supported adaptation for Japan. Author / co-author of various manuscripts based on the results
  • DLBCL – Currently working on the production of a NICE and SMC submission for a CAR-T in DLBCL
  • Epilepsy (cannabidiol) – Validation of a model built by another agency and input into post-submission support following questions regarding model validity
  • Epilepsy – Developed a cost-effectiveness model and health economics sections of positive submissions for a new medication for the treatment of prolonged acute seizures to the SMC and the AWMSG. Adapted the model for use in Ireland, Germany, Spain, France, Switzerland and Italy, including development of Delphi panel surveys to fill data gaps. Lead author on a suite of poster publications and manuscripts based upon the analyses
  • Erectile dysfunction – led development of cost minimisation modelling and economic writeup for successful SMC and AWMSG submissions for an injectable product
  • Gastric cancer – Provision of strategic advice and input to the development of global materials including SLR, NMA, landscaping and economic modelling for an immunotherapy product
  • Gaucher’s disease and ulcerative colitis-associated dysplasia – Provided strategic advice and technical input to the development of ultra-orphan submissions to NICE and the CADTH
  • Giant cell arteritis – Provision of technical QC and strategic advice for the development of both global and UK submission information
  • Glioblastoma – Provision of strategic advice and development of feasibility assessment for a new product for multiple potential indications
  • Hepatitis C – Provided strategic advice and QC for the development of economic models and submission dossiers for two NICE and SMC submissions
  • Hepatocellular carcinoma – Designed an early economic model to inform strategy for a device designed for use in HCC. Provided technical and strategic advice for production of quality of life (mapping) and survival analysis from clinical trial data
  • Hereditary angioedema – Developed an economic model for use in later submissions in the UK and US and conducted quality of life analysis to determine the key drivers of changes of quality of life in this ultra-orphan condition to inform value story and economic model development
  • Hypercholesterolaemia – Project lead for development of an economic model for submission to NICE
  • Idiopathic pulmonary fibrosis – Provided strategic advice and technical input to the development and use in cost-effectiveness analysis of survival analyses based upon Phase III and long-term extension study data. Project lead for the development of economic sections of a NICE dossier, including representation of the manufacturer at NICE including subsequent appeals
  • Immune thrombocytopenic purpura – Developed a modular model assessing cost effectiveness within ITP in the UK, publication and adaptation of the model for use within 10 other countries. The model included a very complex treatment sequence approach and used a high level of user-friendly design and VBA coding to make the model as adaptable as possible for other country use
  • Immunology – Strategic input to the development of a tool to help payers and prescribers to define the appropriate use of previously marketed products and their biosimilars, and new innovative treatments, in line with the clinical trend towards personalized treatment
  • IV iron – Developed cost-minimisation models in the UK, Spain, Italy and Germany for a new IV iron treatment for anaemia in CKD
  • Mantle cell lymphoma (first line) – Provided project leadership and conducted economic modelling as part of the development of a global economic model for first-line MCL and clinical and economic systematic reviews. Strategic approaches had to be devised for handling issues with paucity of follow-up for survival and quality of life data, second-line treatments and indirect comparison to other relevant therapies where no formal network was available. Conducted an advisory board to gain clinician input to model development. Submitted of the economic model to the SMC and NICE
  • Mantle cell lymphoma (second-line) – Project lead for a submission to NICE. Provision of strategic advice and substantial adaptation of the global model to account for differences in comparators, new clinical trial data and the requirement for use of surrogate outcomes information
  • Metastatic and adjuvant melanoma – Developed and led the development of multiple submissions and economic models within first- and second-line metastatic and adjuvant melanoma including combination regimens. Models developed in Excel and used for feasibility assessment and successful submissions to NICE, the SMC and the NCPE, with complex curve fitting and production and analysis of utility mapping data to support submissions within a complicated disease area where progression is not necessarily linked to decreased utility or decreased overall survival. Communication of results via posters/publication. Represented the client at multiple AC meetings
  • Mock Committee meetings – conduct of a large (>20) number of mock NICE appraisal Committee meetings to prepare the manufacturer representative for later challenges
  • Multiple myeloma – Developed and led the development of multiple submissions and economic models in Excel for two products at multiple lines of treatment for NICE, SMC, AWMSG and NCPE submissions and adapted/input to the adaptation of these models for use in other countries (including Estonia, Slovenia, Slovakia, Canada, France, the Netherlands and South Korea). This included survival curve fitting to clinical trial data, development of complex multivariable parametric models to allow for the use of indirect comparative evidence and GEE regression analysis to develop a further model for quality of life. Represented the client at AC meetings. Led the development of a treatment sequencing model for internal use to guide product development and commercial strategies. Currently working on an economic model for a new CAR-T within multiple myeloma
  • Multiple sclerosis – Provided strategic advice and technical and strategic QC for NICE, SMC and NCPE submissions for three products in MS (RRMS and PPMS). Provision of strategic advice for development of a Delphi panel process to gather resource use in PPMS
  • Myelodysplastic syndrome – Developed a cost-utility model suitable for a NICE submission and use within other countries, with survival and response curve fitting for clinical trial data including logistic regression to identify important covariates and adjustments for crossover. Lead writer on the health economics sections of the NICE submission. Represented the client at the NICE AC meeting
  • Myelofibrosis – Provided project leadership as part of the development of a global economic model (discrete event simulation) and NICE submission for myelofibrosis and clinical and economic systematic reviews. Key issues included low patient numbers in the available Phase III trial evidence (orphan disease) and short-term follow-up (48 weeks), necessitating the use of surrogate outcomes to model survival
  • Nocturia – Led the development of an early economic model. Analysis of data gaps and next steps to fill key strategic needs
  • Non-small cell and small cell lung cancer – Provided strategic advice for the development of economic models and submission dossiers for multiple NICE submissions (I-Os and ALK+ve)
  • Prostate cancer – Developed an economic model for submission in Sweden, Norway, South Korea and Wales within locally advanced prostate cancer, answering SMC questions on a model originally developed by another consultancy and turning an original negative recommendation into a positive one. Provided strategic advice and expert technical input for the development of an economic model and submission write for NICE and SMC.  Provided strategic advice for the development of a later economic model and submission write up  for NICE and SMC
  • RCC – Provided strategic advice for the development of economic models and submission dossiers
  • Rheumatoid arthritis – Provided strategic advice for the development of a global simulation model for a new RA product
  • Secondary hyperparathyroidism – Provided strategic and technical QC of models for two products in SHPT. Provided strategic advice on data sources, handling of crossover and survival analysis. Conducted economic and clinical literature reviews to inform model development
  • Short bowel syndrome – Strategic advice on communication with the DSU for an ultra-orphan product filtered down the NICE STA route struggling with lack of evidenc
  • Spasticity post stroke – Provided strategic advice for the development of a NICE MTA. Adaptation and input into global model development including health state definition, utility analysis, investigation of stopping rules and extrapolation of short-term trial transition matrices. Feasibility assessment and input into clinical trial design for later HTA use
  • Ulcerative colitis – Developed an economic model suitable for an SMC submission for a new steroid formulation for UC. Conducted advisory boards to gain clinician input to model development
  • Uterine fibroids – Led development of early and submission modelling and HTA writeup for successful SMC and AWMSG submissions

 

Publications

View Dawn’s publication history in our database

 

Memberships

  • ISPOR Oncology Modeling group
  • ISPOR Open Source Models group
  • ISPOR Health State Utility Values group

 

Referee/Reviewer roles

Journals:

  • Medical Decision Making
  • Pharmacoeconomics

 

Back to Our Board

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies